U937
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
U937 |
Humane Histiozytische Leukämie Zell-Linie |
300368 |
cryovial |
265,00 |
U937 |
Humane Histiozytische Leukämie Zell-Linie |
330368 |
vital |
335,00 |
| Designation: | U-937 |
| Depositor: | Koren |
| Organism: | Homo sapiens (human) |
| Ethnicity: | Caucasian |
| Age/Stage: | 37 years |
| Gender: | male |
| Tissue: | lymphoma, histiocytic |
| Celltype: | monocyte-macrophage, histiocyte |
| Growth Properties: | suspension |
| Culture Medium: | RPMI 1640 medium supplemented with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1.0 mM sodium pyruvate and 10% fetal bovine serum |
| Subculturing: | Cultures can be maintained by addition or replacement of fresh medium. Establish new cultures at 0.1 to 1 X 105 viable cells/ml. Maximum cell density at 1 to 2 X 106 cells/ml. |
| Fluid Renewal: | add fresh medium every 3 to 4 days |
| Freeze Medium: | CM-1 (CLS ∙ Cell Lines Service) |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| Receptors Expressed: | immunoglobulin (Fc); complement (C3) |
| Products: | lysozyme; beta-2-microglobulin (beta 2 microglobulin); tumor necrosis factor (TNF), also known as tumor necrosis factor alpha (TNF-alpha, TNF alpha), after stimulation with phorbol myristic acid (PMA) |
References: Sundstrom C et al. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 17: 565-77, 1976. Ralph P et al. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J Exp Med 143: 1528-33, 1976. Koren HS et al. In vitro activation of a human macrophage-like cell line. Nature 279: 328-31, 1979. Gidlund M et al. Natural killer cells kill tumour cells at a given stage of differentiation. Nature 292: 848-50, 1981. Olsson I et al. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholecalciferol. Cancer Res. 43: 5862-7, 1983. Morimoto H et al. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res 53: 2591-6, 1993. Giovannangeli C et al. Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target. Proc Natl Acad Sci USA 94: 79-84, 1997. Brigino E et al. Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. Proc Natl Acad Sci USA 94: 3178-82, 1997. Ramos AM et al. Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis. J Cell Physiol 209: 1006-15, 2006. Uesato N et al. JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model. Exp Hematol 34: 1385-92, 2006. | |
